Physician profile
Fred Bearison
NPI 1174614853
$4,336.42
in general payments reported to CMS, 2019-2025
35 companies · $82.23 in 2025
The $82.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.71 · 2020: $30.56 · 2021: $556 · 2022: $1,344 · 2023: $1,400 · 2024: $861 · 2025: $82.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $598.60 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $586.43 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $350.14 | 2021-2023 | |
| Abbvie INC. | $310.45 | 2021-2025 | Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $290.44 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $275.97 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $266.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.22 | 2020-2024 | Jardiance, Tradjenta |
| Abbott Laboratories | $204.70 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $185.25 | 2021-2024 | Repatha, Otezla |
| Ge Healthcare | $165.49 | 2022-2023 | |
| Pfizer INC. | $82.58 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $72.54 | 2022 | |
| Astellas Pharma US INC | $64.19 | 2023-2024 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $62.87 | 2023 | Austedo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $55.02 | 2022 | |
| Merck Sharp & Dohme LLC | $53.25 | 2021-2022 | |
| Esperion Therapeutics, INC. | $48.34 | 2021-2022 | |
| Biogen, INC. | $42.56 | 2021 | |
| Inari Medical, INC. | $40.24 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $39.57 | 2022-2023 | Quviviq |
| Argenx US, INC. | $35.98 | 2023 | Vyvgart |
| Lucid Diagnostics INC. | $34.68 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $28.26 | 2021-2022 | |
| Averitas Pharma INC. | $27.69 | 2023 | Qutenza |
| Banner Life Sciences, LLC | $24.61 | 2022 | |
| Lundbeck LLC | $23.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.40 | 2021 | |
| Daiichi Sankyo INC. | $20.94 | 2024 | Injectafer |
| Mdd US Operations, LLC | $17.23 | 2023 | Gocovri |
| Allergan, INC. | $16.24 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.43 | 2022 | |
| Zyla Life Sciences, INC. | $13.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Bearison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.